Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 16,591

Document Document Title
WO/2018/012901A1
The present invention relates to a pharmaceutical composition for cell protection containing cyclo histidine-proline (cyclo His-Pro, CHP) as an active ingredient. The pharmaceutical composition for cell protection containing cyclo histid...  
WO/2018/006667A1
Disclosed are antihypertensive peptides and antihypertensive proteins and a use thereof. The amino acid sequences of the antihypertensive peptides are respectively TTW, VHW and KAKW, and the amino acid sequences of the antihypertensive p...  
WO/2018/007495A1
The present invention relates to compounds of formula (I) and compositions comprising them for use in enhancing umami taste and/ or saltiness of a food product.  
WO/2018/007496A1
The present invention relates to compounds and compositions for use in enhancing flavor and/or saltiness of a food product. Particularly, the present invention relates to compounds of the general formula I) and compositions comprising them.  
WO/2018/008902A1
The present invention relates to a psoriasis-induced animal model and a use thereof and, more particularly, to: a psoriasis-induced animal model transformed such that a Pellino homolog 1 (Peli1) gene is overexpressed according to the adm...  
WO/2018/000079A1
Novel cyclic peptide GHRP-6 analogs of formula (I): (I) or pharmaceutically acceptable esters or salts thereof, are described. These cyclic peptide GHRP-6 analogs may be used for modulating CD36 activity, for example for the treatment of...  
WO/2018/001332A1
A compound having an inhibitory activity against a mutant isocitrate dehydrogenase, a preparation method therefor and use thereof, particularly a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or an ena...  
WO/2018/004281A2
Disclosed are a tranexamic acid-peptide having a skin whitening effect and skin whitening activity with excellent thermal stability and time stability, which is capable of inducing return to healthy skin and whitening effect through skin...  
WO/2018/001273A1
Provided are a peptide or a salt thereof, and a preparation method therefor. The peptide may be selected from VVYP, AVLP, IGFP, LLIIVP and STAP. The preparation method comprises steps as follows: using a resin as a starting material, lin...  
WO/2018/005332A1
Endomorphin-2 and tetrapeptide derivatives thereof are described. Pharmaceutical or cosmetic compositions containing endomorphin-2 or a tetrapeptide derivative thereof are therapeutically effective to treat, improve or prevent pain in hu...  
WO/2017/223098A1
Compositions comprising bis(tryptophan) derivatives are provided that act as antimicrobials. Also provided are methods for reversing antibiotic resistance in a bacterium, or recovering or enhancing antimicrobial activity of an antibiotic...  
WO/2017/219808A1
Provided are a compound as shown in formula (I) usable as a hepatitis C virus inhibitor, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, usable to treat hepatitis C virus (HCV) infections or hepa...  
WO/2017/217535A1
Provided is a novel peptide having an ACE inhibitory activity. More particularly, provided is a tripeptide comprising Leu-Arg-Ala.  
WO/2017/217728A1
The present invention relates to: a composition for promoting angiogenesis, a pharmaceutical composition for preventing or treating angiogenesis-dependent diseases, and a quasi-drug and cosmetic composition for skin regeneration, all of ...  
WO/2017/217855A1
Disclosed are geminoid peptide-like compound according to Formula (I): R1 - C(=0) - Zn - NR3 - R2 in which R1 and R2 are each independently saturated, partly saturated or unsaturated, straight, branched or cyclic alkyl chains, wherein R1...  
WO/2017/216177A1
The peptide has from 3 to 10 amino acids comprising at least the sequence K*(Ac)GH or K*(Ac)HG and may further comprise an N-terminus modification, preferably an acylation, and/or a C-terminus modification; K* is selected from the group ...  
WO/2017/211818A1
The present invention relates to a compound of formula (I), wherein X is C=0, C=S or B-OH; Y is an electrophile and Z is a leaving group, or Y══Z is an electrophile; R1 comprises or consists of (a) (i) a first group binding to a prot...  
WO/2017/214534A1
The invention provides a copper-mediated process for making compounds according to Formula (I): that are the macrocyclic scaffolds of the arylomycin class of biologically active compounds, where R1, R2, R3, RA1, RA2, RA3, B, G1, G2, PG, ...  
WO/2017/214076A1
The present invention describes rhomboid protease inhibitors having high specificity and inhibition characteristics providing novel antibiotics, anti-malarial pharmaceutical agents, and provides a strategy for designing RiBns (rhomboid-i...  
WO/2017/211272A1
The present invention provides a phenyl propanamide derivative as represented by formula (I), a manufacturing method of the derivative, application of the derivative as a κ-opioid receptor (KOR) agonist, and application of the derivativ...  
WO/2017/207546A1
The present invention relates to washing or cleaning compositions, preferably liquid washing compositions, comprising at least one protease, at least one compound of the formula (I) and/or of the formula (II) that acts as a protease inhi...  
WO/2017/209805A1
A variety of hydrophobically modified polypeptoids are provided. The hydrophobically modified polypeptoids can include a polyamide backbone having a random copolymer of two or more different types of repeat units, where one or more of th...  
WO/2017/205392A1
The present invention provides polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein. The invention also provides methods of maki...  
WO/2017/204606A1
The present invention relates to a cytosol-penetrating antibody and a use thereof, and specifically, to a light chain variable region and/or heavy chain variable region positioned in a cytosol, a cytosol-penetrating antibody containing s...  
WO/2017/201624A1
A transdermal formulation which can be applied to the skin as a latex-free hypoallergenic adhesive patch or transdermal delivery cream using a combination of glutathione, Vitamin D, glycol, sodium bicarbonate and base cream resilient in ...  
WO/2017/201433A1
The disclosure provides methods of preventing or treating mitochondrial myopathy in a mammalian subject, reducing risk factors associated with mitochondrial myopathy, and/or reducing the likelihood or severity of mitochondrial myopathy. ...  
WO/2017/197386A1
Methods for diagnosing, treating, and monitoring the treatment of mucormycosis are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having m...  
WO/2017/193562A1
A water soluble rapamycin derivative modified by glutathione and represented by formula I and a preparation method therefor. Definition to R1 and R2 is described in the specification. A compound represented by the formula I can be used f...  
WO/2017/193757A1
Provided are a water-soluble Epothilone derivative represented by formula (I), a preparation method therefor and an intermediate thereof, and an application thereof in preparation of drugs for inhibiting growth of tumor cells.  
WO/2017/197303A1
This disclosure is directed to novel apicidin methods and compositions for the inhibition of quorum sensing in bacterial infections and novel apicidin methods and compositions for treating a staphylococcal infection.  
WO/2017/181437A1
Provided is a non-amino acid method for chemical total synthesis of polypeptides. Said non-amino acid method for chemical total synthesis of polypeptides uses as a raw material ketoamide compounds, which are synthesized into a polypeptid...  
WO/2017/184520A1
Embodiments of the invention include compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders...  
WO/2017/184670A3
Provided are methods for treating Zika virus infections by administering a compound selected from:  
WO/2017/184670A2
Provided are methods for treating Zika virus infections by administering a compound of Formula I, Formula II, Formula III, or Formula IV, or combinations thereof.  
WO/2017/179838A1
The present invention provides a peptide having anti-inflammatory activity, composed of an amino acid sequence of a sequence listing of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3. The peptide inhibits the expression of inflammatory cytok...  
WO/2017/178333A1
The present invention discloses retro-inverso peptides and pharmaceutical composition containing them. The peptides of the invention prevent key events occurring during the metastatic process, i.e. invasion of the extracellular matrix, f...  
WO/2017/180064A1
The invention relates to medicine and veterinary applications, in particular, as a means for effective control of acute and/or chronic pain, and may be used in emergency medicine for the treatment of acute and/or chronic pain, including ...  
WO/2017/178950A1
Disclosed herein is an improved 4+4 solution phase synthesis of Lanreotide acetate. The process comprises coupling of two suitably protected tetrapeptide fragments which on deprotection, oxidation, followed by treatment with acetic acid ...  
WO/2017/179647A1
A peptide is provided which has a binding inhibitory function that inhibits binding between amylospheroids (ASPD) and neurons. The polypeptide, represented by expression (I) or (II), is synthesized, isolated or purified. X1X2X3X4 (I) In ...  
WO/2017/175107A1
Disclosed herein is an improved 4+4 solution phase synthesis of octreotide acetate. The process comprises coupling of two suitably protected tetrapeptide fragments which on deprotection, oxidation, and treatment with acetic acid provides...  
WO/2017/176460A3
Neuropeptide S receptor agonists are provided. The NPS agonists include trimeric, tetrameric, pentameric or hexameric peptidomimetic analogs exhibiting affinity for and activity at the neuropeptide S receptor. The peptidomimetic molecule...  
WO/2017/176460A2
Neuropeptide S receptor agonists are provided. The NPS agonists include trimeric, tetrameric, pentameric or hexameric peptidomimetic analogs exhibiting affinity for and activity at the neuropeptide S receptor. The peptidomimetic molecule...  
WO/2017/170637A1
The purpose of the present invention is to provide a compound that has at the C-terminus a functional group utilizable for formation of a complex and that exhibits cell toxicity. Provided by the present invention is a peptide derivative ...  
WO/2017/170924A1
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This i...  
WO/2017/160124A2
The present invention relates to a recombinant expression vector for producing a water-soluble norovirus vaccine, and more particularly, to a recombinant expression vector for producing a water-soluble norovirus vaccine, and a method for...  
WO/2017/160118A2
The present invention relates to a novel peptide for improving the expression efficiency of a target protein, and to a fusion protein including same. A novel peptide according to the present invention may improve the expression efficienc...  
WO/2017/161144A1
The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors as therapeutics and imaging agents. The prese...  
WO/2017/159554A1
The invention provides a crystal of glutathione having excellent flowability and pulverizability, and a method for producing the same. The invention relates to a crystal of reduced-form glutathione, wherein the average crystal thickness ...  
WO/2017/159555A1
The purpose of the invention is to provide: a crystal of reduced-form glutathione in which the content of impurities, particularly L-cysteinyl-L-glycine, is reduced; and a method for producing the same. The invention relates to a crystal...  
WO/2017/157213A1
The present invention relates to a compound represented by formula (I), chemical synthesis preparation of dual-functional conjugates capable of inhibiting tumors and tumor metastasis, and tumor resistance effects. In the present inventio...  

Matches 1 - 50 out of 16,591